Instruction for use: Oxyprogesterone capronate solution for injections in oleum

Active substance Hydroxyprogesterone caproate

ATX code G03DA03 Hydroxyprogesterone

Pharmacological group

Estrogens, gestagens; Their homologues and antagonists

Antineoplastic hormonal agents and hormone antagonists

Nosological classification (ICD-10)

C50 Malignant neoplasm of breast

Cancer of the nipple and areola of the breast, Breast carcinoma, The hormone-dependent form of recurrent breast cancer in women in menopause, Hormone-dependent breast cancer, Disseminated breast carcinoma, Disseminated Breast Cancer, Malignant breast cancer, Malignant neoplasm of breast, Contralateral breast cancer, Locally advanced or metastatic breast cancer,Locally-distributed breast cancer, Locally-recurring breast cancer, Metastatic breast carcinoma, Metastasis of breast tumors, Metastatic breast carcinoma, Inoperable breast carcinoma, Incompatible breast cancer, Breast cancer in women with metastases, Breast cancer in men with metastases, Breast Cancer, Breast cancer in men, Mammary cancer, Breast cancer with distant metastases, Breast cancer in postmenopausal women, Breast cancer hormone-dependent, Breast cancer with local metastases, Breast cancer with metastases, Breast cancer with regional metastases,Breast cancer with metastases, Common hormone-dependent forms of breast cancer, Common Breast Cancer, Recurrent Breast Cancer, Recurrence of breast tumors, Breast cancer, Estrogen-dependent breast cancer, Estrogen-Dependent Breast Cancer, Disseminated breast cancer with overexpression of HER2, Tumors of the mammary glands

C53 Malignant neoplasm of cervix uteri

Intraepithelial neoplasm of cervix, Cervical carcinoma, Cervical cancer

C54 Malignant neoplasm of uterus

Uterine cancer, Cancer of the body of the uterus, Sarcoma of the uterus

N91 Lack of menstruation, meager and rare menstruation

Amenorrhea, Amenorrhea hypogonadotropic, Amenorrhea is prolactin-dependent, Oligomenorrhoea, Shortening of the secretory phase of the menstrual cycle, Menstrual disorders, Menstruation disorders, Prolactin-dependent amenorrhea without galactorrhea

N92 Abundant, frequent and irregular menstruation

Metromenorragii, Menorrhagia, Menorrhagia primary, Polymenorea, Idiopathic menorrhagia, Menorrhagia, Functional metronormorragia, Primary menorrhagia

N96 Habitual miscarriage

Miscarriage habitual, Habitual abortion, Habitual miscarriage

O20.0 Threatened abortion

Abortion threatening, threatening miscarriage, Spastic conditions with the risk of abortion, Threatened miscarriage in the first trimester of pregnancy, The threat of miscarriage, threatened abortion, The threat of miscarriage, Threatened spontaneous miscarriage

Composition and form of release

1 ampoule with 1 ml solution for injection in peach or olive oil contains 125 mg hydroxyprogesterone (12.5%) mg; In the box 10 pcs.

pharmachologic effect

Pharmacological action - progestagenic.

Indications

Habitual and threatening miscarriage in the first half of pregnancy, amenorrhea and polymenorrhea, uterine cancer, breast cancer.

Contraindications

The second half of pregnancy.

Side effects

Tachycardia.

Dosing and Administration

Intramuscularly (intramuscularly), 125-250 mg once a week during the first half of pregnancy. In amenorrhea primary or secondary - 250 mg once or in 2 divided doses. For polymenorrhea, 65-125 mg per 20-22 day of the cycle.

Storage conditions

In the dark place.

Keep out of the reach of children.

Shelf life

5 years.

Do not use after the expiry date printed on the package.